The pharmaceutical industry is under ever increasing compound or a set of compounds that are known to bind pressure to increase its success rate in bringing drugs to to the desired target, and use this knowledge to identify the market. Current efforts within the industry are directed other compounds with similar properties in databases. This at reducing the hit-to-drug timeline and increasing the is usually achieved by similarity and substructure number of quality candidate drugs that make the transition searching 6 or pharmacophore matching 7 from discovery to the clinical phase. Enormous advances in matching 8 . However, when the structure of the receptor genomics have resulted in large increase in the number of is available, both pharmacophore-based and docking potential therapeutic targets. This growth in potential targets techniques can be employed. The latter method involves has increased the demand for reliable target validation, as positioning each ligand into the binding site of the target, well as technologies that can identify rapidly several quality thus proposing a binding mode and affinity for each lead candidates [1] [2] [3] [4] . Virtual screening (VS) technology is compound in the database. This information is then used gaining increasing importance in the discovery process to rank the compounds in order to select and or 3D shape because it is a reliable and inexpensive method for identifying lead molecules 5 . It is seen as a complementary approach to high-throughput screening (HTS) and when coupled with structural biology, it enhances the success rate of identification of leads. Further, the advances in computational techniques have enabled VS to make a deep impact on the drug discovery process.
The tools for carrying out VS can be broadly categorized as receptor-based or ligand-based. The ligand-based methods use information provided by a *For correspondence E-mail: evans@bcpindia.org experimentally test a small subset of hits for biological activity. In particular, both these methods can be synergistically integrated to improve the drug design and development process.
This article is intended to provide an overview of methods, in particular docking and pharmacophore searching, along with commercial and non-commercial software for in silico screening of ligand databases and some successful examples in this arena.
DATABASE STRUCTURE
The primary requirement for performing VS, by either or Cambridge Structural Database (CSD) 10 can be employed for this purpose. Additionally, a database of known reagents and compounds which are readily synthesizable can be used for VS after primary filtration for 'drug-like' properties 2 such as variation of Lipinski's rule-of-five 11 , number of rotatable bonds or the polar surface area. A database could also be filtered to remove theoretical method such as comparative modelling). The 3D structure of the receptor is corrected and transformed into an appropriate format depending on the requirements of the docking program. The docking method then samples the conformational space of the binding site and scores each possible ligand pose, which is then taken as the predicted binding mode of that ligand. The ligand and receptor flexibility is an important aspect in VS because the conformations of the ligand, as well as the receptor binding site residues, might be different from their conformation in the bound state. The method.
compounds with specific substructures associated with aspects of ligand and receptor flexibility are tackled to poor chemical stability or toxicity. Also, physically some extent in some of the docking programs (flexible relevant ionization and tautomeric states should be search) or by pre-computing a DB of several conformers assigned to compounds in the DB. It is prudent to use all of each compound to be screened, as mentioned in the the relevant tautomers because there is no way of previous section. A majority of the docking programs knowing a priori which tautomer is most likely to bind to explore ligand flexibility through a variety of algorithms. 
VS USING DOCKING
The docking process involves the simulation of molecular recognition events using the 3D structure of the receptor (obtained by X-ray crystallography or NMR or a Majority of the docking methods treat the receptor as a rigid entity, which is an inaccurate but necessary approximation in order to limit the complexity and consequently the computational cost required to accurately sample the flexibility of the binding site. www.ijpsonline.com incorporate protein mobility through rotamer libraries for flexible side chains and by use of an ensemble of protein structures to generate Boltzman-weighted grids with which the docking function is generated 19 .
The next important step that determines the success of the docking process is ranking the quality of different poses of the same molecule and then with respect to other molecules in the DB (Scoring). There are several scoring functions 20 available to achieve this task. Force field-based scoring functions such as AMBER 21 , (Accelrys Inc., USA) and PLP 29 use an empirical scoring function to rank different poses. The GOLD scoring function has been validated on a large data set 30 and uses a genetic algorithm to rank the poses, and it is considered to be a reliable docking and scoring algorithm for VS. Another class of scoring functions, knowledgebased, is derived from the structures of ligand-receptor complexes using statistical mechanics. In contrast to empirical scoring functions, they do not require binding affinity data of ligand-receptor complexes and so are free to use information in ligand-receptor complexes deposited of several scoring functions such as PLP, ChemScore and Dock found little or no correlation between predicted and experimental binding affinities. Therefore, it becomes crucial to use a post-analysis strategy to minimize the false positives in the selection list. In consensus scoring strategy [36] [37] [38] , a docking function is used to generate topranked poses and then multiple scoring functions are used to score these poses. Then, only the top-ranked compounds common to each scoring method are chosen for biological evaluation. It has been observed that almost all docking methods are able to identify the correct binding pose 39 but usually cannot rank it as the topranked binding pose for the ligand. Therefore, it is prudent to use consensus scoring of multiple poses rather than a top-ranked single pose.
Based on the above known limitations, it is strongly advisable to use a set of ligands with known binding fig. 1 .
At the end of the docking process, a set of best compounds is selected. It is not advisable to select the compounds merely on the basis of scoring or 'best ranking'. A recent study 35 that evaluated the performance modes and affinities, and multiple docking and scoring (consensus) algorithms, to calibrate the docking methodology for the target under study before undertaking VS of large databases.
VS USING PHARMACOPHORE METHODS
The docking methodologies discussed above help in screening databases only when the 3D structure of the target receptor is available. In the early phase of drug discovery, or in cases where the structure elucidation is beyond the capabilities of present day techniques, the docking technique cannot be used. A pharmacophore-based ( w w w www.ijpsonline.com search of databases can be carried out in absence of the receptor structure with the help of the information available from a set of ligands binding preferentially to the given receptor. The credit for first conceiving the concept of the pharmacophore goes to Paul Ehrlich, who devised a way (in early 1900s) to develop dyes through chromophores (i.e., the part of a molecule responsible for imparting colour) 40 . A good review of the evolution and history of the pharmacophore concept has been published by Peter Gund 41 , who is also the author of the modern definition of a pharmacophore -"a set of elsewhere 41 . For timely reviews in the field, the reader may follow other references [64] [65] [66] [67] [68] .
Pharmacophore modelling provides a useful framework for better understanding of the existing data and can be used as a predictive tool in the design of compounds with improved potency, selectivity and/or pharmacokinetic properties. Pharmacophore models are generated by analyzing structure-activity-relationships and mapping common structural features of active analogues. The pharmacophore can be identified by structural features in a molecule that is recognized at a receptor site and is responsible for that molecule's biological activity" 42, 43 . The concept could not achieve its full utilization until the development of 3D database searching software in 1990. MOLPAT 44 57 (Accelrys Inc., USA). The critical demand for the pharmacophore recognition software arose when the direct method (using a receptor-ligand complex) or by indirect method (using only a collection of ligands that have experimentally been observed to interact with a given receptor). However, direct methods are becoming extremely important because of the increase in the rate at which protein structures are being determined. A flow chart of steps involved in VS by the pharmacophore method is depicted in fig. 2 . www.ijpsonline.com
Set of Ligands

Pharmacophore generation:
Pharmacophore generation starts with the selection of a set of ligands for which the pharmacophore model is to be constructed. The type of ligand molecules, the size of the dataset and its diversity have a great impact on the resulting pharmacophore model 67 . The Carnell-Smith method 69 , RAPID 70 and HipHop 59, 64, 71 assume that ligands have the same activity and thus do not consider activity data. The information of inactive ligands can also be used to indicate structural features that significantly decrease the activity. The programs that use information of inactive combined to form a representation of the whole structure. The RAPID method represents ligand structures as a set of labelled points in three-dimensional space, where each point is associated with a feature 70 . Another approach by Takahashi et al. 76 represents a ligand structure through a labelled graph, with nodes representing the features and the edges representing the relations. Different methods that use this representation are given in the literature 77 . In another approach, a ligand structure is considered a set of labelled points, together with the associated interpoint distances 77 . This type of representation is orientation ligands are CLEW 72 and the current version of DISCO 58 . independent, in contrast to the 3D point-set representation. Pharmacophore models can also be used to predict the activity of unknown compounds. For deriving such
The features extracted from different ligand molecules models, HypoGen 63 utilizes a large enough set of diverse are matched and pharmacophore candidates are compounds (about 18-30) with different activity levels (4-5
proposed. This is called pattern identification. A pattern or orders of magnitude). Most of the currently available configuration is a set of relative locations in 3D space, methods such as HipHop, HypoGen, MPHIL 73 and each associated with a feature. A ligand is said to match a RAPID are designed to handle small (less than 100 pattern if it possesses a set of features and a ligands) data sets. Other methods use larger data sets as conformation such that the features can be superimposed input but convert them into a smaller one by sorting the with the corresponding locations. The most popular activities of the ligands, depending on a user-specified approach to define a pattern is to find the maximal cut-off. Lastly, one should remember that though the common substructure (MCS). The methods that have dataset should be as diverse as possible to get an adopted this approach are DISCO 58 , RAPID 70 accurate pharmacophore model, very different ligands GAMMA 78 and GASP 60 . This approach assumes that a may bind at different binding sites, resulting in a common pharmacophore is responsible for the observed misleading pharmacophore model 74 .
activity. This is an inaccurate assumption in the MCS approach and can be overcome by relaxing the In the next step, the features relevant to the requirements ("Relax MCS" approach) that all input pharmacophore model are extracted from the input ligands possess all the features. This philosophy is used ligands (feature extraction). Features can be defined in the MPHIL 74 method. depending on topology (phenyl ring and carbonyl group), function (H-bond donor/acceptor, acid, base, Algorithms for pattern identification have also been aromatic ring and hydrophobic group) and atom (3D developed. (For a detailed description, see reference 67). position of an atom and its type) 67 . Both topology-based
The Clique detection algorithm [79] [80] [81] has been implemented and function-based features have some drawbacks. For in DISCO and MPHIL methods. Clique detection has its example, hydroxyl oxygen can be classified as both an Horigin in graph theory. A clique is a subgraph in which , bond donor and acceptor. A simple way to represent a functional group is by its centre. The centre of an acid, base, H-bond donor/acceptor is usually defined as the position of an actual atom. For a hydrophobic region or an aromatic ring, the centre is defined as the centroid of the group. Furthermore, a vector representation is more accurate than a point representation since it imposes an additional constraint on bond directionality between the ligand feature and its complementary feature on the receptor 71, 75 . In addition, a hydrophobic group can be represented by a sphere and an aromatic ring by a plane and its normal.
From each ligand structure, the selected features are every node is connected to every other node. The Clique detection algorithm finds the largest clique in a reference graph which is also present in every other graph in the set. HipHop and SCAMPI use an exhaustive search algorithm in which the search for a pattern starts with small sets of features and extends until no larger common pattern exists. HypoGen uses a similar approach but also incorporates activity information into the pharmacophore derivation process. This is done in three steps: the constructive stage identifies pharmacophore candidates that are common among the set of most active ligands, followed by the subtractive stage in which those pharmacophore candidates identified in the constructive stage and also present in more than half of the least www.ijpsonline.com active ligands are removed; and the last step of optimization attempts to improve the score of the pharmacophore candidates that pass the subtractive stage by simulated annealing 67 . GASP 60 and GAMMA 78 are based on the genetic algorithm 82 and also perform a conformational search as part of the GA run. Thus, molecular flexibility is simulated by generating multiple conformations of the given ligand followed by an exploration of different ways to align the molecules and to identify the pharmacophore pattern.
performed to find novel scaffolds of DNA gyrase inhibitors 83 . The ACD database of 350,000 compounds and a portion of the Roche compound inventory (RCI) were screened to obtain 150 weak inhibitors. These novel DNA gyrase inhibitors binding to the ATP-binding site have seven structurally different scaffolds. The optimization of the indazole scaffold provided a DNA gyrase inhibitor which was 10 times more potent than novobiocin.
Sterol metabolism:
In the last step of pharmacophore generation, candidates
Laggner and colleagues 84 have reported pharmacophore are scored and ranked. A lower score indicates a greater models for three protein targets involved in sterol possibility that the model is a result of chance correlation.
metabolism. Twenty-three structurally diverse molecules A detailed description of scoring methods implemented in with binding affinity data for EBP (emopamil binding techniques that relax the MCS requirements, and scoring protein), ERG2 (fungal counterpart of EBP) and the in genetic algorithms like GASP and GAMMA is given in sigma-1 receptor were used in the study to derive a the literature 59, 67 .
pharmacophore model with the HypoGen module of Catalyst. These three enzymes of sterol metabolism share As mentioned in the introductory section, VS by high affinity for various structurally diverse compounds. pharmacophore searching is more efficient when Three pharmacophore models with one positive ionizable structural knowledge of the target receptor is available.
group and four hydrophobic features in common but with The receptor-based approach for pharmacophore different spatial arrangements were derived and validated. generation involves analyzing features of the active site
The study showed that the hydrogen-bonding and the spatial relationship among them, and then an interactions are not required for high-affinity inhibitor active image of this is used to construct the binding. The models were subsequently used to search pharmacophore model. Such an operation gives rise to a the database [such as World Drug Index (WDI), Kyoto large number of features, and it is necessary to Encyclopedia of Genes and Genomes (KEGG) and determine which of these are actually parts of the COMPOUND database]. In virtual screening, the drugs pharmacophore. The method begins with a 3D structure that were reported previously to bind to one or several of the receptor (usually in PDB format) and a set of of these proteins were retrieved along with 11 new hits, ligands with known activity. Using the information of the which were then tested experimentally. Inhibitors with active site residues (from biochemical or structural nanomolar binding affinity were discovered. studies), a program such as Ludi 25, 28 (Accelrys Inc., USA) generates an interaction map which is a complement of
CAN ONE PROTECT KNOWLEDGE-
the receptor-binding site. The ligands with known activity
BASED CONCEPTS?
are used to identify the functional features such as Hbond donors/acceptors and lipophilic groups from the interaction map in the active site. Often it is necessary to filter/limit the number of features since queries with multiple features may fail to retrieve any hits from the database. Therefore, 3D queries composed of fewer features are generated by considering all possible combinations. Catalyst 57 uses these queries to search the ligand database.
SUCCESSFUL APPLICATION OF VS METHODS
DNA gyrase inhibitors:
A 3D database search using Ludi and Catalyst was The answer is now YES. Though there are no patents yet of QSAR studies, the pharmacophores are being protected under Intellectual Property Rights. The credit for the first application of patenting such a knowledgebased concept goes to Biogen. In 1998, Biogen applied for a world patent of pharmacophores (WO 98/04913) in which all compounds derived from a 3D database search of the described pharmacophore were included. Peptor Ltd. filed a patent (US 6,343,257) that involves the development of a pharmacophore, its use in VS and use of the hits to design new compounds. Another patent of pharmacophores covers Hepatitis C NS3 protease inhibitors. This patent (WO 98/46630) claims all compounds that fit the pharmacophore model that in turn www.ijpsonline.com
